Rosatom will experience a unique tool for nuclear medicine of the future

Experts from leading scientific centers of the state Corporation "Rosatom" physics and energy Institute named after Leypunsky (IPPE, Obninsk, Kaluga region) intend this year to test unparalleled in the world of complex for producing radioactive isotope actinium-225, which is believed will determine the future of nuclear medicine.

This was stated by the Director, FEI Andrew Goverdovsky in an interview to the official edition of the Russian nuclear industry newspaper "Rosatom Country".

In nuclear medicine for the treatment of various forms of cancer are becoming more popular so-called alpha emitter- a radioactive isotope with its decay emits alpha particles. Such particles allow the targeted solely to kill tumor cells without damaging healthy tissue. Therefore, alpha emitters are often called "future of nuclear medicine".

One of the most promising alpha-emitter is actinium-225 (AC-225), a radioisotope with a half life of about 10 days. AC-225 can be used independently to control malignant tumors, such as prostate cancer, and to get child radioisotope bismuth-213 is also used in Oncology for the treatment of many forms of cancer. But Ac-225 in the world now is small, so its cost is very high.

Earlier, the FEI has launched a project on creation of a complex for producing actinium-225 so-called medical quality. "This is probably our most important project not only in nuclear medicine, but generally in directorey applied physics," said Goverdovsky.

According to the Director, this project occupied almost all of FEI: chemists, physicists, mathematicians, materials scientists, and physics.

"Last year, made a mathematical and theoretical model, a prototype generator. All patented. This year's experience, next I hope to begin production. Unique in the world, ahead of all of two to three years," said Goverdovsky.

Earlier it was reported that this development will allow FEI to actinium-225 is much cheaper than abroad.